$3.71 Bn Vaccine Contract Manufacturing Market – Global Forecast to 2025 with Cumulative Impact of COVID-19 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Vaccine Contract Manufacturing Market Research Report by Function, by Applications – Global Forecast to 2025 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering.

The Global Vaccine Contract Manufacturing Market is expected to grow from USD 1,891.79 Million in 2019 to USD 3,711.34 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 11.88%.

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Vaccine Contract Manufacturing Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report answers questions such as:

1. What is the market size and forecast of the Global Vaccine Contract Manufacturing Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Vaccine Contract Manufacturing Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Vaccine Contract Manufacturing Market?

4. What is the competitive strategic window for opportunities in the Global Vaccine Contract Manufacturing Market?

5. What are the technology trends and regulatory frameworks in the Global Vaccine Contract Manufacturing Market?

6. What are the modes and strategic moves considered suitable for entering the Global Vaccine Contract Manufacturing Market?

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

3.1. Market Outlook

3.2. Function Outlook

3.3. Type Outlook

3.4. Applications Outlook

3.5. Geography Outlook

3.6. Competitor Outlook

4. Market Overview

4.1. Introduction

4.2. Vaccine Contract Manufacturing Market, By Geography

5. Market Dynamics

5.1. Introduction

5.1.1. Drivers

5.1.1.1. Increasing demand for vaccines leading to capacity expansion by contract manufacturers

5.1.1.2. Paradigm shift toward cell-based vaccine production

5.1.1.3. Key advantages such as cost and time saving offered by contract services

5.1.1.4. Vaccination coverage across the globe

5.1.2. Restraints

5.1.2.1. Limited outsourcing by well-established vaccine manufacturers

5.1.3. Opportunities

5.1.3.1. Rising global demand to cater to the growing population of varied age groups

5.1.3.2. Innovation and robust vaccine pipeline

5.1.3.3. Favorable government insights and guidelines to speed up the vaccine manufacturing

5.1.4. Challenges

5.1.4.1. Pharma companies manufacturing operations in-house to gain strategic control

6. Market Insights

6.1. Porters Five Forces Analysis

6.1.1. Threat of New Entrants

6.1.2. Threat of Substitutes

6.1.3. Bargaining Power of Customers

6.1.4. Bargaining Power of Suppliers

6.1.5. Industry Rivalry

6.2. Cumulative Impact of COVID-19

6.3. Client Customizations

6.3.1. Supply Chain Trend Associated with COVID-19

6.3.2. Automation in Vaccine Development

6.3.3. Collaborative Landscape among Bioprocessing Companies

7. Global Vaccine Contract Manufacturing Market, By Function

7.1. Introduction

7.2. Downstream

7.2.1. Analytical & QC studies

7.2.2. Fill & Finish Operations

7.2.3. Packaging

7.3. Upstream

7.3.1. Bacterial Expression Systems

7.3.2. Baculovirus/Insect Expression Systems

7.3.3. Mammalian Expression Systems

7.3.4. Yeast Expression Systems

8. Global Vaccine Contract Manufacturing Market, By Type

8.1. Introduction

8.2. Attenuated Vaccine

8.3. DNA Vaccines

8.4. Inactivated Vaccine

8.5. Subunit Vaccines

8.6. Toxoid Vaccines

9. Global Vaccine Contract Manufacturing Market, By Applications

9.1. Introduction

9.2. Human Use

9.3. Veterinary

10. Americas Vaccine Contract Manufacturing Market

11. Asia-Pacific Vaccine Contract Manufacturing Market

12. Europe, Middle East & Africa Vaccine Contract Manufacturing Market

13. Competitive Landscape

13.1. FPNV Positioning Matrix

13.1.1. Quadrants

13.1.2. Business Strategy

13.1.3. Product Satisfaction

13.2. Market Ranking Analysis

13.3. Market Share Analysis

13.4. Competitive Scenario

13.4.1. Merger & Acquisition

13.4.2. Agreement, Collaboration & Partnership

13.4.3. New Product Launch & Enhancement

13.4.4. Investment & Funding

14. Company Usability Profiles

14.1. Ajinomoto Althea, Inc.

14.2. Albany Molecular Research, Inc.

14.3. Catalent, Inc.

14.4. Cobra Bio

14.5. Cytovance Biologics

14.6. FUJIFILM Diosynth Biotechnologies

14.7. GlaxoSmithKline PLC

14.8. ICON PLC

14.9. IDT Biologika

14.10. KBI Biopharma

14.11. LONZA

14.12. Merck KGaA

14.13. Paragon Bioservices, Inc.

14.14. Pfizer, Inc.

14.15. Pharmaceutical Product Development, LLC

14.16. PRA Health Sciences

For more information about this report visit https://www.researchandmarkets.com/r/1kvr14

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900